+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
R

Actively Recruiting

Researchers are comparing durvalumab immunotherapy to the usual post-surgery observation approach for people with early-stage non-small cell lung cancer who have no remaining cancer cells after standard treatment. This phase III trial focuses on patients with stage II to IIIB disease who achieved a complete response following neoadjuvant chemo-immunotherapy. The study aims to find out whether durvalumab can help patients live longer and prevent cancer from coming back compared to just monitoring after surgery. Participants are randomly assigned to one of two groups. One group receives durvalumab intravenously once every 28 days for up to 12 cycles, provided there is no disease progression or unacceptable side effects. The other group undergoes active surveillance without additional treatment for 12 months. During the trial, all participants have regular CT scans and blood samples taken. After treatment or surveillance, patients are followed annually for up to 10 years. Throughout the study, participants complete questionnaires assessing quality of life and symptoms. Researchers monitor disease-free survival, overall survival, and adverse events up to 10 years after randomization. The trial also collects specimens and images for future research. Participants have regular visits for scans, blood tests, and assessments to evaluate the safety and effects of durvalumab compared to observation.

Age: 18Years +All GendersPhase 3
284 locations
P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations
S

Actively Recruiting

Researchers are evaluating whether 6 months of HER2-targeted therapy is as effective as 12 months for treating early-stage HER2-positive breast cancer in patients who have no remaining invasive cancer after preoperative chemotherapy with trastuzumab. The study aims to compare recurrence-free survival and quality of life between shorter and longer treatment durations. Secondary goals include assessing serious side effects, overall survival, local cancer recurrence, and patient-reported symptoms. Participants are randomly assigned to either 6 months or 12 months of HER2-targeted therapy using trastuzumab and possibly pertuzumab, given intravenously or subcutaneously every 21 days. Treatment continues up to 9 or 17 cycles unless disease progresses or side effects are unacceptable. During the trial, participants undergo heart function tests ECHO or MUGA, imaging such as mammography, ultrasound, or MRI, and may provide blood and tissue samples for research. After treatment, participants are followed every 6 months for 5 years or until cancer recurrence, then annually up to 10 years. Researchers monitor recurrence-free survival and quality of life using validated questionnaires. Safety is closely tracked through adverse event reporting, and long-term outcomes including overall survival and brain metastasis occurrence are assessed to understand treatment impact.

Age: 18Years +All GendersPhase 3
702 locations
C

Actively Recruiting

Researchers are evaluating two treatment approaches for patients with high anatomic stage breast cancer that has a low risk of returning. This phase III trial compares standard hormone therapy combined with ribociclib to chemotherapy followed by hormone therapy and ribociclib. Ribociclib works by blocking enzymes needed for tumor growth, and hormone therapy reduces estrogen levels to help stop the growth of cancer cells that depend on estrogen. Chemotherapy works differently by killing or stopping the division and spread of tumor cells. Participants are first screened using the Oncotype DX test to assess their recurrence risk. Those with scores between 0 and 25 are randomized into one of two groups. One group receives their physicians choice of chemotherapy followed by hormone therapy letrozole, anastrozole, or exemestane plus ribociclib. The other group receives hormone therapy plus ribociclib without chemotherapy. Hormone therapy is taken daily for at least 60 months, and ribociclib is taken daily for up to 3 years unless disease progression or unacceptable side effects occur. Throughout the study, participants may undergo imaging scans such as CT, bone scans, or FDG PET-CT scans, and may optionally provide blood samples. Participants are monitored with follow-up visits every 3 months for the first year, every 6 months during years 1 to 5, and annually from years 5 to 10 after randomization. Researchers will assess invasive breast cancer-free survival as the main outcome, along with disease-free survival, overall survival, recurrence measures, and both short- and long-term side effects. The study also plans to collect tumor tissue and blood samples to support future research. Total participation may last up to 10 years to evaluate long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
248 locations